Longer term research required for telehealth

In contrast to claims that telehealth can solve numerous healthcare problems, including access to care, a paper published in the Journal of Medical Internet Research says research on the practice is overly positive because it is often based on short-term projects.

Written by members of the Transatlantic Telehealth Research Network, the paper calls for future research to study the impact and effective use of telehealth.

"Future research is needed to identify additional factors that promote telehealth acceptance, such as human-technology interaction, organization of the healthcare system and social factors," the authors, led by Birthe Dinesen, MS, PhD, of Denmark’s Aalborg University, wrote.

Cost estimates of U.S. telehealth programs from the Congressional Budget Office are geared to short-term financial costs of new legislation rather than potential long-term savings, the authors say.

A personalized telemedicine program must match technology to patient needs, they wrote, noting the patients most likely to benefit from telehealth technology probably need the most help using them.

Read the paper.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.